• Mashup Score: 0
    Don't Miss a Beat: oHCM and Mavacamten - 2 year(s) ago

    Listen to this episode from Don’t Miss a Beat on Spotify. A first-in-class allosteric and reversible inhibitor selective for cardiac myosin approved based on the results of the EXPLORER-HCM trial, mavacamten was approved for the treatment of adults with symptomatic NYHA class 2-3 obstructive hypertrophic cardiomyopathy after their phase 3 data indicated use was with improved exercise capacity,…

    Source: Spotify
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of SJGreene_md
      SJGreene_md

      This month on #DontMissABeat, @mvaduganathan & I were honored to discuss #EXPLORER_HCM & #mavacamten w/ guest #HCM expert @tikuowens! ✅trial design &🔑results ✅#RCT endpoint considerations for #HCM ✅magnitude of KCCQ benefit ✅implementation https://t.co/PuT52ErjAq https://t.co/V1tGs4I8lP

  • Mashup Score: 0
    Bristol Myers Squibb’s Mavacamten Poised to Stand unchallenged - 2 year(s) ago

    May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) market, achieving around $958 million in sales by 2025, according to GlobalData, a leading data and analytics company. Sarah Bundra, Pharmaceutical Analyst at GlobalData, commented: “Mavacamten will be the first drug to specifically target obstructive HCM, which is a common…

    Source: DAIC
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DAICeditor
      DAICeditor

      @DAICeditor @bmsnews #Mavacamten estimated sales just shy of $1 billion if approved for common #cardiomyopathy subtype, says #GlobalData: https://t.co/FJDK7qHa2w #VALOR_HCM #ClinicalTrials #ACC22

  • Mashup Score: 0
    CAMZYOS™ (mavacamten) REMS Resources - 2 year(s) ago

    Find downloadable resources for prescribers, pharmacies, and patients participating in the CAMZYOS™ REMS program.

    Source: www.camzyosrems.com
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of MasriAhmadMD
      MasriAhmadMD

      https://t.co/Chc9ccfd6n In this link you can find many resources for the #mavacamten #REMS program. Will rely heavily on the clinicians and the certified pharmacies. Also you can review the REMS program and sign up if you plan to prescribe mavacamten. #CardioTwitter

  • Mashup Score: 1
    FDA approves mavacamten, first treatment for obstructive hypertrophic cardiomyopathy - 2 year(s) ago

    The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first cardiac myosin inhibitor to be permitted for use in the United States, Bristol Myers Squibb announced.Mavacamten (Camzyos, Bristol Myers Squibb) is the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      ICYMI: “This is a first-in-class medicine specifically for patients living with symptomatic obstructive HCM,” @US_FDA #CardoTwitter #Mavacamten https://t.co/CHponBH8Cb

Load More